Estrogens in rheumatoid arthritis; the immune system and bone

Molecular and Cellular Endocrinology

Volumn 335, Issue 1, 2011, Pages 14-29

  Islander, Ulrika ^a   Jochems, Caroline ^a   Lagerquist, Marie K ^a   Forsblad d'Elia, Helena ^a   Carlsten, Hans ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Bone; Estrogen; Immune system; Rheumatoid arthritis; Selective estrogen receptor modulators

Indexed keywords

2 METHOXYESTRADIOL; ALENDRONIC ACID; BAZEDOXIFENE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; COLECALCIFEROL; COLLAGEN TYPE 2; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ETHINYLESTRADIOL; ETIDRONIC ACID; FULVESTRANT; GAMMA INTERFERON; GESTAGEN; GLUCOCORTICOID; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; LASOFOXIFENE; PARATHYROID HORMONE; PRASTERONE; PRASTERONE SULFATE; RALOXIFENE; RISEDRONIC ACID; SOMATOMEDIN C; STRONTIUM RANELATE; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA;

APOPTOSIS; ARTHRITIS; AUTOIMMUNITY; B LYMPHOCYTE; BIOACCUMULATION; BONE; BONE EROSION; BONE METABOLISM; BREAST CANCER; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL ACTIVITY; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE COURSE; ERYTHROCYTE SEDIMENTATION RATE; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; IMMUNE SYSTEM; IMMUNOSTIMULATION; ISCHEMIC HEART DISEASE; NONHUMAN; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PATHOGENESIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BINDING; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; STROKE;

ANIMALS; ARTHRITIS, RHEUMATOID; BONE AND BONES; CYTOKINES; ESTROGENS; FEMALE; GONADAL STEROID HORMONES; HORMONE REPLACEMENT THERAPY; HUMANS; IMMUNE SYSTEM; LYMPHOCYTES; MALE; MENOPAUSE; OSTEOPOROSIS, POSTMENOPAUSAL; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SEX FACTORS;

EID: 79951580018     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2010.05.018     Document Type: Review

References (326)

1. Abbas A.K., Murphy K.M., Sher A. Functional diversity of helper T lymphocytes. Nature 1996, 383:787-793.
2. Abrahamsen B., Bonnevie-Nielsen V., Ebbesen E.N., Gram J., Beck-Nielsen H. Cytokines and bone loss in a 5-year longitudinal study - hormone replacement therapy suppresses serum soluble interleukin-6 receptor and increases interleukin-1-receptor antagonist: the Danish Osteoporosis Prevention Study. J. Bone Miner. Res. 2000, 15:1545-1554.
3. Adachi J.D., Bensen W.G., Brown J., Hanley D., Hodsman A., Josse R., Kendler D.L., Lentle B., Olszynski W., Ste-Marie L.G., Tenenhouse A., Chines A.A. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N. Engl. J. Med. 1997, 337:382-387.
4. Afzali B., Lombardi G., Lechler R.I., Lord G.M. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin. Exp. Immunol. 2007, 148:32-46.
5. al-Janadi N., al-Dalaan A., al-Balla S., Raziuddin S. CD4+ T cell inducible immunoregulatory cytokine response in rheumatoid arthritis. J. Rheumatol. 1996, 23:809-814.
6. Anderson D.M., Maraskovsky E., Billingsley W.L., Dougall W.C., Tometsko M.E., Roux E.R., Teepe M.C., DuBose R.F., Cosman D., Galibert L. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997, 390:175-179.
7. Anderson G.L., Limacher M., Assaf A.R., Bassford T., Beresford S.A., Black H., Bonds D., Brunner R., Brzyski R., Caan B., Chlebowski R., Curb D., Gass M., Hays J., Heiss G., Hendrix S., Howard B.V., Hsia J., Hubbell A., Jackson R., Johnson K.C., Judd H., Kotchen J.M., Kuller L., LaCroix A.Z., Lane D., Langer R.D., Lasser N., Lewis C.E., Manson J., Margolis K., Ockene J., O'Sullivan M.J., Phillips L., Prentice R.L., Ritenbaugh C., Robbins J., Rossouw J.E., Sarto G., Stefanick M.L., Van Horn L., Wactawski-Wende J., Wallace R., Wassertheil-Smoller S. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004, 291:1701-1712.
8. Aronica S.M., Katzenellenbogen B.S. Progesterone receptor regulation in uterine cells: stimulation by estrogen, cyclic adenosine 3',5'-monophosphate, and insulin-like growth factor I and suppression by antiestrogens and protein kinase inhibitors. Endocrinology 1991, 128:2045-2052.
9. Arron J.R., Choi Y. Bone versus immune system. Nature 2000, 408:535-536.
10. Barrett J.H., Brennan P., Fiddler M., Silman A.J. Does rheumatoid arthritis remit during pregnancy and relapse postpartum? Results from a nationwide study in the United Kingdom performed prospectively from late pregnancy. Arthritis Rheum. 1999, 42:1219-1227.
11. Barrett J.H., Brennan P., Fiddler M., Silman A. Breast-feeding and postpartum relapse in women with rheumatoid and inflammatory arthritis. Arthritis Rheum. 2000, 43:1010-1015.
12. Bekesi G., Tulassay Z., Racz K., Feher J., Szekacs B., Kakucs R., Dinya E., Riss E., Magyar Z., Rigo J. The effect of estrogens on superoxide anion generation by human neutrophil granulocytes: possible consequences of the antioxidant defense. Gynecol. Endocrinol. 2007, 23:451-454.
13. Bekker P.J., Holloway D., Nakanishi A., Arrighi M., Leese P.T., Dunstan C.R. The effect of a single dose of osteoprotegerin in postmenopausal women. J. Bone Miner. Res. 2001, 16:348-360.
14. Benten W.P., Stephan C., Lieberherr M., Wunderlich F. Estradiol signaling via sequestrable surface receptors. Endocrinology 2001, 142:1669-1677.
15. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003, 362:419-427.
16. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., Weiner H.L., Kuchroo V.K. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
17. Bettelli E., Oukka M., Kuchroo V.K. T(H)-17 cells in the circle of immunity and autoimmunity. Nat. Immunol. 2007, 8:345-350.
18. Bijlsma J.W., Huber-Bruning O., Thijssen J.H. Effect of oestrogen treatment on clinical and laboratory manifestations of rheumatoid arthritis. Ann. Rheum. Dis. 1987, 46:777-779.
19. Blais J., Demers D. The use of norethynodrel (Envoid) in the treatment of rheumatoid arthritis. Arthritis Rheum. 1962, 5:284.
20. Bond A., Ratkay L.G., Waterfield J.D., Hay F.C. Post-partum flare in MRL-lpr/lpr mice is associated with a parallel increase of N-acetylglucosamine on serum IgG. Br. J. Rheumatol. 1997, 36:174-177.
21. Bonewald L.F., Dallas S.L. Role of active and latent transforming growth factor beta in bone formation. J. Cell. Biochem. 1994, 55:350-357.
22. Brahn E., Banquerigo M.L., Lee J.K., Park E.J., Fogler W.E., Plum S.M. An angiogenesis inhibitor, 2-methoxyestradiol, involutes rat collagen-induced arthritis and suppresses gene expression of synovial vascular endothelial growth factor and basic fibroblast growth factor. J. Rheumatol. 2008, 35:2119-2128.
23. Brennan P., Silman A. Breast-feeding and the onset of rheumatoid arthritis. Arthritis Rheum. 1994, 37:808-813.
24. Brennan P., Bankhead C., Silman A., Symmons D. Oral contraceptives and rheumatoid arthritis: results from a primary care-based incident case-control study. Semin. Arthritis Rheum. 1997, 26:817-823.
25. Bromley M., Woolley D.E. Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. Arthritis Rheum. 1984, 27:968-975.
26. Bucay N., Sarosi I., Dunstan C.R., Morony S., Tarpley J., Capparelli C., Scully S., Tan H.L., Xu W., Lacey D.L., Boyle W.J., Simonet W.S. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998, 12:1260-1268.
27. Buckley L.M., Leib E.S., Cartularo K.S., Vacek P.M., Cooper S.M. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 1996, 125:961-968.
28. Burgess T.L., Qian Y., Kaufman S., Ring B.D., Van G., Capparelli C., Kelley M., Hsu H., Boyle W.J., Dunstan C.R., Hu S., Lacey D.L. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J. Cell Biol. 1999, 145:527-538.
29. Buyon J.P., Korchak H.M., Rutherford L.E., Ganguly M., Weissmann G. Female hormones reduce neutrophil responsiveness in vitro. Arthritis Rheum. 1984, 27:623-630.
30. Buzas E.I., Hollo K., Rubliczky L., Garzo M., Nyirkos P., Glant T.T. Effect of pregnancy on proteoglycan-induced progressive polyarthritis in BALB/c mice: remission of disease activity. Clin. Exp. Immunol. 1993, 94:252-260.
31. Cao D., Malmstrom V., Baecher-Allan C., Hafler D., Klareskog L., Trollmo C. Isolation and functional characterization of regulatory CD25brightCD4+ T cells from the target organ of patients with rheumatoid arthritis. Eur. J. Immunol. 2003, 33:215-223.
32. Carlsten H., Tarkowski A. Histocompatibility complex gene products and exposure to oestrogen: two independent disease accelerating factors in murine lupus. Scand. J. Immunol. 1993, 38:341-347.
33. Carlsten H., Holmdahl R., Tarkowski A., Nilsson L.A. Oestradiol- and testosterone-mediated effects on the immune system in normal and autoimmune mice are genetically linked and inherited as dominant traits. Immunology 1989, 68:209-214.
34. Carlsten H., Tarkowski A., Holmdahl R., Nilsson L.A. Oestrogen is a potent disease accelerator in SLE-prone MRL lpr/lpr mice. Clin. Exp. Immunol. 1990, 80:467-473.
35. Carlsten H., Nilsson N., Jonsson R., Backman K., Holmdahl R., Tarkowski A. Estrogen accelerates immune complex glomerulonephritis but ameliorates T cell-mediated vasculitis and sialadenitis in autoimmune MRL lpr/lpr mice. Cell Immunol. 1992, 144:190-202.
36. Castagnetta L.A., Carruba G., Granata O.M., Stefano R., Miele M., Schmidt M., Cutolo M., Straub R.H. Increased estrogen formation and estrogen to androgen ratio in the synovial fluid of patients with rheumatoid arthritis. J. Rheumatol. 2003, 30:2597-2605.
37. Cenci S., Weitzmann M.N., Roggia C., Namba N., Novack D., Woodring J., Pacifici R. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J. Clin. Invest. 2000, 106:1229-1237.
38. Chabaud M., Durand J.M., Buchs N., Fossiez F., Page G., Frappart L., Miossec P. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum. 1999, 42:963-970.
39. Chen D., Zhao M., Mundy G.R. Bone morphogenetic proteins. Growth Factors 2004, 22:233-241.
40. Chenu C., Pfeilschifter J., Mundy G.R., Roodman G.D. Transforming growth factor beta inhibits formation of osteoclast-like cells in long-term human marrow cultures. Proc. Natl. Acad. Sci. USA 1988, 85:5683-5687.
41. Cheung J., Mak Y.T., Papaioannou S., Evans B.A., Fogelman I., Hampson G. Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene. J. Endocrinol. 2003, 177:423-433.
42. Chu C.Q., Swart D., Alcorn D., Tocker J., Elkon K.B. Interferon-gamma regulates susceptibility to collagen-induced arthritis through suppression of interleukin-17. Arthritis Rheum. 2007, 56:1145-1151.
43. Cohen A., Dubbs A., Myers A. The treatment of atrophic arthritis with estrogenic substance. N. Engl. J. Med. 1940, 222:140-142.
44. Cohen S.B., Dore R.K., Lane N.E., Ory P.A., Peterfy C.G., Sharp J.T., van der Heijde D., Zhou L., Tsuji W., Newmark R. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum. 2008, 58:1299-1309.
45. Collin-Osdoby P., Rothe L., Anderson F., Nelson M., Maloney W., Osdoby P. Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J. Biol. Chem. 2001, 276:20659-20672.
46. Crotti T.N., Smith M.D., Weedon H., Ahern M.J., Findlay D.M., Kraan M., Tak P.P., Haynes D.R. Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. Ann. Rheum. Dis. 2002, 61:1047-1054.
47. Cummings S.R., Eckert S., Krueger K.A., Grady D., Powles T.J., Cauley J.A., Norton L., Nickelsen T., Bjarnason N.H., Morrow M., Lippman M.E., Black D., Glusman J.E., Costa A., Jordan V.C. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation. JAMA 1999, 281:2189-2197.
48. Cummings S.R., Ensrud K., Delmas P.D., LaCroix A.Z., Vukicevic S., Reid D.M., Goldstein S., Sriram U., Lee A., Thompson J., Armstrong R.A., Thompson D.D., Powles T., Zanchetta J., Kendler D., Neven P., Eastell R. Lasofoxifene in postmenopausal women with osteoporosis. N. Engl. J. Med. 2010, 362:686-696.
49. Curtis S.W., Washburn T., Sewall C., DiAugustine R., Lindzey J., Couse J.F., Korach K.S. Physiological coupling of growth factor and steroid receptor signaling pathways: estrogen receptor knockout mice lack estrogen-like response to epidermal growth factor. Proc. Natl. Acad. Sci. USA 1996, 93:12626-12630.
50. del Junco D.J., Annegers J.F., Luthra H.S., Coulam C.B., Kurland L.T. Do oral contraceptives prevent rheumatoid arthritis?. JAMA 1985, 254:1938-1941.
51. Dolhain R.J., van der Heiden A.N., ter Haar N.T., Breedveld F.C., Miltenburg A.M. Shift toward T lymphocytes with a T helper 1 cytokine-secretion profile in the joints of patients with rheumatoid arthritis. Arthritis Rheum. 1996, 39:1961-1969.
52. Doran M.F., Pond G.R., Crowson C.S., O'Fallon W.M., Gabriel S.E. Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis Rheum. 2002, 46:625-631.
53. Doran M.F., Crowson C.S., O'Fallon W.M., Gabriel S.E. The effect of oral contraceptives and estrogen replacement therapy on the risk of rheumatoid arthritis: a population based study. J. Rheumatol. 2004, 31:207-213.
54. Dore R.K., Cohen S.B., Lane N.E., Palmer W.R., Shergy W., Zhou L., Wang H., Tsuji W., Newmark R. Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann. Rheum. Dis. 2010, 69:872-875.
55. Eastell R., Devogelaer J.P., Peel N.F., Chines A.A., Bax D.E., Sacco-Gibson N., Nagant de Deuxchaisnes C., Russell R.G. Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Osteoporos. Int. 2000, 11:331-337.
56. Egan P.J., van Nieuwenhuijze A., Campbell I.K., Wicks I.P. Promotion of the local differentiation of murine Th17 cells by synovial macrophages during acute inflammatory arthritis. Arthritis Rheum. 2008, 58:3720-3729.
57. Eghbali-Fatourechi G., Khosla S., Sanyal A., Boyle W.J., Lacey D.L., Riggs B.L. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J. Clin. Invest. 2003, 111:1221-1230.
58. Ehinger M., Vestberg M., Johansson A.C., Johannesson M., Svensson A., Holmdahl R. Influence of CD4 or CD8 deficiency on collagen-induced arthritis. Immunology 2001, 103:291-300.
59. Emery P., Fleischmann R., Filipowicz-Sosnowska A., Schechtman J., Szczepanski L., Kavanaugh A., Racewicz A.J., van Vollenhoven R.F., Li N.F., Agarwal S., Hessey E.W., Shaw T.M. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006, 54:1390-1400.
60. Engdahl C., Jochems C., Windahl S.H., Borjesson A.E., Ohlsson C., Carlsten H., Lagerquist M.K. Amelioration of collagen-induced arthritis and immune-associated bone loss through signaling via estrogen receptor alpha, and not estrogen receptor beta or G protein-coupled receptor 30. Arthritis Rheum. 2010, 62:524-533.
61. Eriksen E.F., Hodgson S.F., Eastell R., Cedel S.L., O'Fallon W.M., Riggs B.L. Cancellous bone remodeling in type I (postmenopausal) osteoporosis: quantitative assessment of rates of formation, resorption, and bone loss at tissue and cellular levels. J. Bone Miner. Res. 1990, 5:311-319.
62. Eriksen E.F., Langdahl B., Vesterby A., Rungby J., Kassem M. Hormone replacement therapy prevents osteoclastic hyperactivity: a histomorphometric study in early postmenopausal women. J. Bone Miner. Res. 1999, 14:1217-1221.
63. Erlandsson M.C., Gomori E., Taube M., Carlsten H. Effects of raloxifene, a selective estrogen receptor modulator, on thymus, T cell reactivity, and inflammation in mice. Cell. Immunol. 2000, 205:103-109.
64. Erlandsson M.C., Ohlsson C., Gustafsson J.A., Carlsten H. Role of oestrogen receptors alpha and beta in immune organ development and in oestrogen-mediated effects on thymus. Immunology 2001, 103:17-25.
65. Erlandsson M.C., Jonsson C.A., Lindberg M.K., Ohlsson C., Carlsten H. Raloxifene- and estradiol-mediated effects on uterus, bone and B lymphocytes in mice. J. Endocrinol. 2002, 175:319-327.
66. Erlandsson M.C., Jonsson C.A., Islander U., Ohlsson C., Carlsten H. Oestrogen receptor specificity in oestradiol-mediated effects on B lymphopoiesis and immunoglobulin production in male mice. Immunology 2003, 108:346-351.
67. Ernestam S., Hafstrom I., Werner S., Carlstrom K., Tengstrand B. Increased DHEAS levels in patients with rheumatoid arthritis after treatment with tumor necrosis factor antagonists: evidence for improved adrenal function. J. Rheumatol. 2007, 34:1451-1458.
68. Ernst M., Rodan G.A. Estradiol regulation of insulin-like growth factor-I expression in osteoblastic cells: evidence for transcriptional control. Mol. Endocrinol. 1991, 5:1081-1089.
69. Ettinger B., Black D.M., Mitlak B.H., Knickerbocker R.K., Nickelsen T., Genant H.K., Christiansen C., Delmas P.D., Zanchetta J.R., Stakkestad J., Gluer C.C., Krueger K., Cohen F.J., Eckert S., Ensrud K.E., Avioli L.V., Lips P., Cummings S.R. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) investigators. JAMA 1999, 282:637-645.
70. Fata J.E., Kong Y.Y., Li J., Sasaki T., Irie-Sasaki J., Moorehead R.A., Elliott R., Scully S., Voura E.B., Lacey D.L., Boyle W.J., Khokha R., Penninger J.M. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 2000, 103:41-50.
71. Filardo E., Quinn J., Pang Y., Graeber C., Shaw S., Dong J., Thomas P. Activation of the novel estrogen receptor G protein-coupled receptor 30 (GPR30) at the plasma membrane. Endocrinology 2007, 148:3236-3245.
72. Fogle R.H., Stanczyk F.Z., Zhang X., Paulson R.J. Ovarian androgen production in postmenopausal women. J. Clin. Endocrinol. Metab. 2007, 92:3040-3043.
73. Forsblad-d'Elia H., Carlsten H. The impact of hormone replacement therapy on humoral and cell-mediated immune responses in vivo in post-menopausal women with rheumatoid arthritis. Scand. J. Immunol. 2008, 68:661-667.
74. Forsblad-D'Elia H., Larsen A., Mattsson L.A., Waltbrand E., Kvist G., Mellstrom D., Saxne T., Ohlsson C., Nordborg E., Carlsten H. Influence of hormone replacement therapy on disease progression and bone mineral density in rheumatoid arthritis. J. Rheumatol. 2003, 30:1456-1463.
75. Forsblad-D'Elia H., Larsen A., Waltbrand E., Kvist G., Mellstrom D., Saxne T., Ohlsson C., Nordborg E., Carlsten H. Radiographic joint destruction in postmenopausal rheumatoid arthritis is strongly associated with generalised osteoporosis. Ann. Rheum. Dis. 2003, 62:617-623.
76. Forsblad-D'Elia H., Mattsson L.A., Ohlsson C., Nordborg E., Carlsten H. Hormone replacement therapy in rheumatoid arthritis is associated with lower serum levels of soluble IL-6 receptor and higher insulin-like growth factor 1. Arthritis Res. Ther. 2003, 5:R202-R209.
77. Forsblad-d'Elia H., Christgau S., Mattsson L.A., Saxne T., Ohlsson C., Nordborg E., Carlsten H. Hormone replacement therapy, calcium and vitamin D3 versus calcium and vitamin D3 alone decreases markers of cartilage and bone metabolism in rheumatoid arthritis: a randomized controlled trial [ISRCTN46523456]. Arthritis Res. Ther. 2004, 6:R457-R468.
78. Fuller K., Murphy C., Kirstein B., Fox S.W., Chambers T.J. TNFalpha potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL. Endocrinology 2002, 143:1108-1118.
79. Galien R., Garcia T. Estrogen receptor impairs interleukin-6 expression by preventing protein binding on the NF-kappaB site. Nucleic Acids Res. 1997, 25:2424-2429.
80. Genovese M.C., Van den Bosch F., Roberson S.A., Bojin S., Biagini I.M., Ryan P., Sloan-Lancaster J. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum. 2010, 62:929-939.
81. Geraldes P., Gagnon S., Hadjadj S., Merhi Y., Sirois M.G., Cloutier I., Tanguay J.F. Estradiol blocks the induction of CD40 and CD40L expression on endothelial cells and prevents neutrophil adhesion: an ERalpha-mediated pathway. Cardiovasc. Res. 2006, 71:566-573.
82. Gerli R., Bistoni O., Russano A., Fiorucci S., Borgato L., Cesarotti M.E., Lunardi C. In vivo activated T cells in rheumatoid synovitis. Analysis of Th1- and Th2-type cytokine production at clonal level in different stages of disease. Clin. Exp. Immunol. 2002, 129:549-555.
83. Gilbert M., Rotstein J., Cunningham C., Estrin I., Davidson A., Pincus G. Norethynodrel with mestranol in treatment of rheumatoid arthritis. JAMA 1964, 190:235.
84. Gilbert L., He X., Farmer P., Boden S., Kozlowski M., Rubin J., Nanes M.S. Inhibition of osteoblast differentiation by tumor necrosis factor-alpha. Endocrinology 2000, 141:3956-3964.
85. Ginaldi L., Di Benedetto M.C., De Martinis M. Osteoporosis, inflammation and ageing. Immun. Ageing 2005, 2:14.
86. Goemaere S., Ackerman C., Goethals K., De Keyser F., Van der Straeten C., Verbruggen G., Mielants H., Veys E.M. Onset of symptoms of rheumatoid arthritis in relation to age, sex and menopausal transition. J. Rheumatol. 1990, 17:1620-1622.
87. Gompel A., Piette J.C. Systemic lupus erythematosus and hormone replacement therapy. Menopause Int. 2007, 13:65-70.
88. Gonzalez D.A., de Leon A.C., Moncholi C.V., Cordova Jde C., Hernandez L.B. Arthritis in mice: allogeneic pregnancy protects more than syngeneic by attenuating cellular immune response. J. Rheumatol. 2004, 31:30-34.
89. Gravallese E.M., Harada Y., Wang J.T., Gorn A.H., Thornhill T.S., Goldring S.R. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am. J. Pathol. 1998, 152:943-951.
90. Gravallese E.M., Manning C., Tsay A., Naito A., Pan C., Amento E., Goldring S.R. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum. 2000, 43:250-258.
91. Green S., Walter P., Greene G., Krust A., Goffin C., Jensen E., Scrace G., Waterfield M., Chambon P. Cloning of the human oestrogen receptor cDNA. J. Steroid Biochem. 1986, 24:77-83.
92. Grimaldi C.M., Cleary J., Dagtas A.S., Moussai D., Diamond B. Estrogen alters thresholds for B cell apoptosis and activation. J. Clin. Invest. 2002, 109:1625-1633.
93. Grimaldi C.M., Jeganathan V., Diamond B. Hormonal regulation of B cell development: 17 beta-estradiol impairs negative selection of high-affinity DNA-reactive B cells at more than one developmental checkpoint. J. Immunol. 2006, 176:2703-2710.
94. Groppe J., Greenwald J., Wiater E., Rodriguez-Leon J., Economides A.N., Kwiatkowski W., Affolter M., Vale W.W., Belmonte J.C., Choe S. Structural basis of BMP signalling inhibition by the cystine knot protein Noggin. Nature 2002, 420:636-642.
95. Gruber C.J., Tschugguel W., Schneeberger C., Huber J.C. Production and actions of estrogens. N. Engl. J. Med. 2002, 346:340-352.
96. Gruber C.J., Gruber D.M., Gruber I.M., Wieser F., Huber J.C. Anatomy of the estrogen response element. Trends Endocrinol. Metab. 2004, 15:73-78.
97. Haddad A., Bienvenu J., Miossec P. Increased production of a Th2 cytokine profile by activated whole blood cells from rheumatoid arthritis patients. J. Clin. Immunol. 1998, 18:399-403.
98. Hall F. Menopausal arthralgia. N. Engl. J. Med. 1938, 219:1015-1026.
99. Hall G.M., Daniels M., Huskisson E.C., Spector T.D. A randomised controlled trial of the effect of hormone replacement therapy on disease activity in postmenopausal rheumatoid arthritis. Ann. Rheum. Dis. 1994, 53:112-116.
100. Hall G.M., Daniels M., Doyle D.V., Spector T.D. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum. 1994, 37:1499-1505.
101. Halme S., von Hertzen L., Bloigu A., Kaprio J., Koskenvuo M., Leinonen M., Saikku P., Surcel H.M. Chlamydia pneumoniae-specific cell-mediated and humoral immunity in healthy people. Scand. J. Immunol. 1998, 47:517-520.
102. Hartigan-O'Connor D.J., Poon C., Sinclair E., McCune J.M. Human CD4+ regulatory T cells express lower levels of the IL-7 receptor alpha chain (CD127), allowing consistent identification and sorting of live cells. J. Immunol. Methods 2007, 319:41-52.
103. Hasegawa J., Nagashima M., Yamamoto M., Nishijima T., Katsumata S., Yoshino S. Bone resorption and inflammatory inhibition efficacy of intermittent cyclical etidronate therapy in rheumatoid arthritis. J. Rheumatol. 2003, 30:474-479.
104. Haugeberg G., Uhlig T., Falch J.A., Halse J.I., Kvien T.K. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register. Arthritis Rheum. 2000, 43:522-530.
105. Haugeberg G., Orstavik R.E., Uhlig T., Falch J.A., Halse J.I., Kvien T.K. Bone loss in patients with rheumatoid arthritis: results from a population-based cohort of 366 patients followed up for two years. Arthritis Rheum. 2002, 46:1720-1728.
106. Haynes D.R., Crotti T.N., Loric M., Bain G.I., Atkins G.J., Findlay D.M. Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology (Oxford) 2001, 40:623-630.
107. Hayward M., Fiedler-Nagy C. Mechanisms of bone loss: rheumatoid arthritis, periodontal disease and osteoporosis. Agents Actions 1987, 22:251-254.
108. Heino T.J., Hentunen T.A., Vaananen H.K. Osteocytes inhibit osteoclastic bone resorption through transforming growth factor-beta: enhancement by estrogen. J. Cell. Biochem. 2002, 85:185-197.
109. Hofbauer L.C., Khosla S., Dunstan C.R., Lacey D.L., Spelsberg T.C., Riggs B.L. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 1999, 140:4367-4370.
110. Holmdahl R., Jansson L., Andersson M. Female sex hormones suppress development of collagen-induced arthritis in mice. Arthritis Rheum. 1986, 29:1501-1509.
111. Holmdahl R., Jansson L., Meyerson B., Klareskog L. Oestrogen induced suppression of collagen arthritis: I. Long term oestradiol treatment of DBA/1 mice reduces severity and incidence of arthritis and decreases the anti type II collagen immune response. Clin. Exp. Immunol. 1987, 70:372-378.
112. Holmdahl R., Carlsten H., Jansson L., Larsson P. Oestrogen is a potent immunomodulator of murine experimental rheumatoid disease. Br. J. Rheumatol. 1989, 28(Suppl. 1):54-58. discussion 69-71.
113. Hooyman J.R., Melton L.J., Nelson A.M., O'Fallon W.M., Riggs B.L. Fractures after rheumatoid arthritis. A population-based study. Arthritis Rheum. 1984, 27:1353-1361.
114. Horwood N.J., Elliott J., Martin T.J., Gillespie M.T. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology 1998, 139:4743-4746.
115. Horwood N.J., Kartsogiannis V., Quinn J.M., Romas E., Martin T.J., Gillespie M.T. Activated T lymphocytes support osteoclast formation in vitro. Biochem. Biophys. Res. Commun. 1999, 265:144-150.
116. Huber C., Collishaw S., Mosley J.R., Reeve J., Noble B.S. Selective estrogen receptor modulator inhibits osteocyte apoptosis during abrupt estrogen withdrawal: implications for bone quality maintenance. Calcif. Tissue Int. 2007, 81:139-144.
117. Hughes D.E., Boyce B.F. Apoptosis in bone physiology and disease. Mol. Pathol. 1997, 50:132-137.
118. Hughes D.E., Dai A., Tiffee J.C., Li H.H., Mundy G.R., Boyce B.F. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat. Med. 1996, 2:1132-1136.
119. Hunt S.M., McKenna S.P., McEwen J., Williams J., Papp E. The Nottingham health profile: subjective health status and medical consultations. Soc. Sci. Med. A 1981, 15:221-229.
120. Imboden J.B. The immunopathogenesis of rheumatoid arthritis. Annu. Rev. Pathol. 2009, 4:417-434.
121. Issekutz A.C., Sapru K. Modulation of adjuvant arthritis in the rat by 2-methoxyestradiol: an effect independent of an anti-angiogenic action. Int. Immunopharmacol. 2008, 8:708-716.
122. Ito Y., Usui T., Kobayashi S., Iguchi-Hashimoto M., Ito H., Yoshitomi H., Nakamura T., Shimizu M., Kawabata D., Yukawa N., Hashimoto M., Sakaguchi N., Sakaguchi S., Yoshifuji H., Nojima T., Ohmura K., Fujii T., Mimori T. Gamma/delta T cells are the predominant source of interleukin-17 in affected joints in collagen-induced arthritis, but not in rheumatoid arthritis. Arthritis Rheum. 2009, 60:2294-2303.
123. Jansson L., Holmdahl R. Oestrogen induced suppression of collagen arthritis. IV: Progesterone alone does not affect the course of arthritis but enhances the oestrogen-mediated therapeutic effect. J. Reprod. Immunol. 1989, 15:141-150.
124. Jansson L., Holmdahl R. Oestrogen-induced suppression of collagen arthritis; 17 beta-oestradiol is therapeutically active in normal and castrated F1 hybrid mice of both sexes. Clin. Exp. Immunol. 1992, 89:446-451.
125. Jansson L., Holmdahl R. Enhancement of collagen-induced arthritis in female mice by estrogen receptor blockage. Arthritis Rheum. 2001, 44:2168-2175.
126. Jilka R.L., Hangoc G., Girasole G., Passeri G., Williams D.C., Abrams J.S., Boyce B., Broxmeyer H., Manolagas S.C. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science 1992, 257:88-91.
127. Jilka R.L., Passeri G., Girasole G., Cooper S., Abrams J., Broxmeyer H., Manolagas S.C. Estrogen loss upregulates hematopoiesis in the mouse: a mediating role of IL-6. Exp. Hematol. 1995, 23:500-506.
128. Jilka R.L., Takahashi K., Munshi M., Williams D.C., Roberson P.K., Manolagas S.C. Loss of estrogen upregulates osteoblastogenesis in the murine bone marrow. Evidence for autonomy from factors released during bone resorption. J. Clin. Invest. 1998, 101:1942-1950.
129. Jimi E., Nakamura I., Ikebe T., Akiyama S., Takahashi N., Suda T. Activation of NF-kappaB is involved in the survival of osteoclasts promoted by interleukin-1. J. Biol. Chem. 1998, 273:8799-8805.
130. Jimi E., Nakamura I., Duong L.T., Ikebe T., Takahashi N., Rodan G.A., Suda T. Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells. Exp. Cell. Res. 1999, 247:84-93.
131. Jochems C., Islander U., Erlandsson M., Verdrengh M., Ohlsson C., Carlsten H. Osteoporosis in experimental postmenopausal polyarthritis: the relative contributions of estrogen deficiency and inflammation. Arthritis Res. Ther. 2005, 7:R837-R843.
132. Jochems C., Islander U., Kallkopf A., Lagerquist M., Ohlsson C., Carlsten H. Role of raloxifene as a potent inhibitor of experimental postmenopausal polyarthritis and osteoporosis. Arthritis Rheum. 2007, 56:3261-3270.
133. Jochems C., Lagerquist M., Hakansson C., Ohlsson C., Carlsten H. Long-term anti-arthritic and anti-osteoporotic effects of raloxifene in established experimental postmenopausal polyarthritis. Clin. Exp. Immunol. 2008, 152:593-597.
134. Josefsson E., Tarkowski A. Suppression of type II collagen-induced arthritis by the endogenous estrogen metabolite 2-methoxyestradiol. Arthritis Rheum. 1997, 40:154-163.
135. Josefsson E., Tarkowski A., Carlsten H. Anti-inflammatory properties of estrogen. I. In vivo suppression of leukocyte production in bone marrow and redistribution of peripheral blood neutrophils. Cell. Immunol. 1992, 142:67-78.
136. Kanda N., Tsuchida T., Tamaki K. Estrogen enhancement of anti-double-stranded DNA antibody and immunoglobulin G production in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Arthritis Rheum. 1999, 42:328-337.
137. Kanik K.S., Wilder R.L. Hormonal alterations in rheumatoid arthritis, including the effects of pregnancy. Rheum. Dis. Clin. North Am. 2000, 26:805-823.
138. Karlstrom, A., Andréasson, E., Karlsson, A., Ohlsson, C., Tivesten, A., Islander, U., Carlsten, H., 2010. 2-methoxyestradiol ameliorates arthritis and osteoporosis in a model of postmenopausal rheumatoid arthritis. Manuscript in preparation.
139. Kehlen A., Pachnio A., Thiele K., Langner J. Gene expression induced by interleukin-17 in fibroblast-like synoviocytes of patients with rheumatoid arthritis: upregulation of hyaluronan-binding protein TSG-6. Arthritis Res. Ther. 2003, 5:R186-R192.
140. Kelchtermans H., De Klerck B., Mitera T., Van Balen M., Bullens D., Billiau A., Leclercq G., Matthys P. Defective CD4+ CD25+ regulatory T cell functioning in collagen-induced arthritis: an important factor in pathogenesis, counter-regulated by endogenous IFN-gamma. Arthritis Res. Ther. 2005, 7:R402-R415.
141. Kelchtermans H., Geboes L., Mitera T., Huskens D., Leclercq G., Matthys P. Activated CD4 + CD25+ regulatory T cells inhibit osteoclastogenesis and collagen-induced arthritis. Ann. Rheum. Dis. 2009, 68:744-750.
142. Koenen H.J., Smeets R.L., Vink P.M., van Rijssen E., Boots A.M., Joosten I. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 2008, 112:2340-2352.
143. Komm B.S., Terpening C.M., Benz D.J., Graeme K.A., Gallegos A., Korc M., Greene G.L., O'Malley B.W., Haussler M.R. Estrogen binding, receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells. Science 1988, 241:81-84.
144. Komuro H., Olee T., Kuhn K., Quach J., Brinson D.C., Shikhman A., Valbracht J., Creighton-Achermann L., Lotz M. The osteoprotegerin/receptor activator of nuclear factor kappaB/receptor activator of nuclear factor kappaB ligand system in cartilage. Arthritis Rheum. 2001, 44:2768-2776.
145. Kong Y.Y., Yoshida H., Sarosi I., Tan H.L., Timms E., Capparelli C., Morony S., Oliveira-dos-Santos A.J., Van G., Itie A., Khoo W., Wakeham A., Dunstan C.R., Lacey D.L., Mak T.W., Boyle W.J., Penninger J.M. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999, 397:315-323.
146. Kong Y.Y., Feige U., Sarosi I., Bolon B., Tafuri A., Morony S., Capparelli C., Li J., Elliott R., McCabe S., Wong T., Campagnuolo G., Moran E., Bogoch E.R., Van G., Nguyen L.T., Ohashi P.S., Lacey D.L., Fish E., Boyle W.J., Penninger J.M. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999, 402:304-309.
147. Kotake S., Sato K., Kim K.J., Takahashi N., Udagawa N., Nakamura I., Yamaguchi A., Kishimoto T., Suda T., Kashiwazaki S. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J. Bone Miner. Res. 1996, 11:88-95.
148. Kotake S., Udagawa N., Takahashi N., Matsuzaki K., Itoh K., Ishiyama S., Saito S., Inoue K., Kamatani N., Gillespie M.T., Martin T.J., Suda T. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J. Clin. Invest. 1999, 103:1345-1352.
149. Kramer P.R., Kramer S.F., Guan G. 17 beta-estradiol regulates cytokine release through modulation of CD16 expression in monocytes and monocyte-derived macrophages. Arthritis Rheum. 2004, 50:1967-1975.
150. Kremer M., Judd J., Rifkin B., Auszmann J., Oursler M.J. Estrogen modulation of osteoclast lysosomal enzyme secretion. J. Cell. Biochem. 1995, 57:271-279.
151. Krishnan V., Wang X., Safe S. Estrogen receptor-Sp1 complexes mediate estrogen-induced cathepsin D gene expression in MCF-7 human breast cancer cells. J. Biol. Chem. 1994, 269:15912-15917.
152. Kuiper G.G., Enmark E., Pelto-Huikko M., Nilsson S., Gustafsson J.A. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. USA 1996, 93:5925-5930.
153. Kushner P.J., Agard D.A., Greene G.L., Scanlan T.S., Shiau A.K., Uht R.M., Webb P. Estrogen receptor pathways to AP-1. J. Steroid Biochem. Mol. Biol. 2000, 74:311-317.
154. Kvien T.K., Glennas A., Knudsrod O.G., Smedstad L.M., Mowinckel P., Forre O. The prevalence and severity of rheumatoid arthritis in Oslo. Results from a county register and a population survey. Scand. J. Rheumatol. 1997, 26:412-418.
155. Kvien T.K., Uhlig T., Odegard S., Heiberg M.S. Epidemiological aspects of rheumatoid arthritis: the sex ratio. Ann. N Y Acad. Sci. 2006, 1069:212-222.
156. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., Elliott R., Colombero A., Elliott G., Scully S., Hsu H., Sullivan J., Hawkins N., Davy E., Capparelli C., Eli A., Qian Y.X., Kaufman S., Sarosi I., Shalhoub V., Senaldi G., Guo J., Delaney J., Boyle W.J. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
157. Lacey D.L., Tan H.L., Lu J., Kaufman S., Van G., Qiu W., Rattan A., Scully S., Fletcher F., Juan T., Kelley M., Burgess T.L., Boyle W.J., Polverino A.J. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am. J. Pathol. 2000, 157:435-448.
158. Lam J., Takeshita S., Barker J.E., Kanagawa O., Ross F.P., Teitelbaum S.L. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 2000, 106:1481-1488.
159. Lane N.E., Sanchez S., Modin G.W., Genant H.K., Pierini E., Arnaud C.D. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J. Clin. Invest. 1998, 102:1627-1633.
160. Lange U., Teichmann J., Muller-Ladner U., Strunk J. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study. Rheumatology (Oxford) 2005, 44:1546-1548.
161. Larsen A. How to apply Larsen score in evaluating radiographs of rheumatoid arthritis in long-term studies. J. Rheumatol. 1995, 22:1974-1975.
162. Levin E.R. G protein-coupled receptor 30: estrogen receptor or collaborator?. Endocrinology 2009, 150:1563-1565.
163. Levy N., Zhao X., Tang H., Jaffe R.B., Speed T.P., Leitman D.C. Multiple transcription factor elements collaborate with estrogen receptor alpha to activate an inducible estrogen response element in the NKG2E gene. Endocrinology 2007, 148:3449-3458.
164. Li X., Takahashi M., Kushida K., Inoue T. The preventive and interventional effects of raloxifene analog (LY117018 HCL) on osteopenia in ovariectomized rats. J. Bone Miner. Res. 1998, 13:1005-1010.
165. Li J., Sarosi I., Yan X.Q., Morony S., Capparelli C., Tan H.L., McCabe S., Elliott R., Scully S., Van G., Kaufman S., Juan S.C., Sun Y., Tarpley J., Martin L., Christensen K., McCabe J., Kostenuik P., Hsu H., Fletcher F., Dunstan C.R., Lacey D.L., Boyle W.J. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc. Natl. Acad. Sci. USA 2000, 97:1566-1571.
166. Lindberg M.K., Moverare S., Skrtic S., Alatalo S., Halleen J., Mohan S., Gustafsson J.A., Ohlsson C. Two different pathways for the maintenance of trabecular bone in adult male mice. J. Bone Miner. Res. 2002, 17:555-562.
167. Lindberg M.K., Weihua Z., Andersson N., Moverare S., Gao H., Vidal O., Erlandsson M., Windahl S., Andersson G., Lubahn D.B., Carlsten H., Dahlman-Wright K., Gustafsson J.A., Ohlsson C. Estrogen receptor specificity for the effects of estrogen in ovariectomized mice. J. Endocrinol. 2002, 174:167-178.
168. Lindberg M.K., Moverare S., Skrtic S., Gao H., Dahlman-Wright K., Gustafsson J.A., Ohlsson C. Estrogen receptor (ER)-beta reduces ERalpha-regulated gene transcription, supporting a " ying yang" relationship between ERalpha and ERbeta in mice. Mol. Endocrinol. 2003, 17:203-208.
169. Ljung L., Olsson T., Engstrand S., Wallberg-Jonsson S., Soderberg S., Rantapaa-Dahlqvist S. Interleukin-1 receptor antagonist is associated with both lipid metabolism and inflammation in rheumatoid arthritis. Clin. Exp. Rheumatol. 2007, 25:617-620.
170. Lubberts E., Joosten L.A., van de Loo F.A., Schwarzenberger P., Kolls J., van den Berg W.B. Overexpression of IL-17 in the knee joint of collagen type II immunized mice promotes collagen arthritis and aggravates joint destruction. Inflamm. Res. 2002, 51:102-104.
171. Lubberts E., Oppers-Walgreen B., Pettit A.R., Van Den Bersselaar L., Joosten L.A., Goldring S.R., Gravallese E.M., Van Den Berg W.B. Increase in expression of receptor activator of nuclear factor kappaB at sites of bone erosion correlates with progression of inflammation in evolving collagen-induced arthritis. Arthritis Rheum. 2002, 46:3055-3064.
172. Macdiarmid F., Wang D., Duncan L.J., Purohit A., Ghilchick M.W., Reed M.J. Stimulation of aromatase activity in breast fibroblasts by tumor necrosis factor alpha. Mol. Cell. Endocrinol. 1994, 106:17-21.
173. MacDonald A.G., Murphy E.A., Capell H.A., Bankowska U.Z., Ralston S.H. Effects of hormone replacement therapy in rheumatoid arthritis: a double blind placebo-controlled study. Ann. Rheum. Dis. 1994, 53:54-57.
174. Manabe N., Kawaguchi H., Chikuda H., Miyaura C., Inada M., Nagai R., Nabeshima Y., Nakamura K., Sinclair A.M., Scheuermann R.H., Kuro-o M. Connection between B lymphocyte and osteoclast differentiation pathways. J. Immunol. 2001, 167:2625-2631.
175. Manel N., Unutmaz D., Littman D.R. The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat. Immunol. 2008, 9:641-649.
176. Mann V., Huber C., Kogianni G., Collins F., Noble B. The antioxidant effect of estrogen and selective estrogen receptor modulators in the inhibition of osteocyte apoptosis in vitro. Bone 2007, 40:674-684.
177. Marks B.R., Nowyhed H.N., Choi J.Y., Poholek A.C., Odegard J.M., Flavell R.A., Craft J. Thymic self-reactivity selects natural interleukin 17-producing T cells that can regulate peripheral inflammation. Nat. Immunol. 2009, 10:1125-1132.
178. Marotte H., Pallot-Prades B., Grange L., Gaudin P., Alexandre C., Miossec P. A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab. Arthritis Res. Ther. 2007, 9:R61.
179. Marotti T., Sirotkovic M., Pavelic J., Gabrilovac J., Pavelic K. In vivo effect of progesteron and estrogen on thymus mass and T-cell functions in female mice. Horm. Metab. Res. 1984, 16:201-203.
180. Masuzawa T., Miyaura C., Onoe Y., Kusano K., Ohta H., Nozawa S., Suda T. Estrogen deficiency stimulates B lymphopoiesis in mouse bone marrow. J. Clin. Invest. 1994, 94:1090-1097.
181. Mattsson R., Mattsson A., Holmdahl R., Whyte A., Rook G.A. Maintained pregnancy levels of oestrogen afford complete protection from post-partum exacerbation of collagen-induced arthritis. Clin. Exp. Immunol. 1991, 85:41-47.
182. McClung M.R., Lewiecki E.M., Cohen S.B., Bolognese M.A., Woodson G.C., Moffett A.H., Peacock M., Miller P.D., Lederman S.N., Chesnut C.H., Lain D., Kivitz A.J., Holloway D.L., Zhang C., Peterson M.C., Bekker P.J. Denosumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 2006, 354:821-831.
183. Mease P.J., Revicki D.A., Szechinski J., Greenwald M., Kivitz A., Barile-Fabris L., Kalsi J., Eames J., Leirisalo-Repo M. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: results of the dose-ranging assessment: international clinical evaluation of rituximab in rheumatoid arthritis (DANCER) trial. J. Rheumatol. 2008, 35:20-30.
184. Messalli E.M., Mainini G., Scaffa C., Cafiero A., Salzillo P.L., Ragucci A., Cobellis L. Raloxifene therapy interacts with serum osteoprotegerin in postmenopausal women. Maturitas 2007, 56:38-44.
185. Miller P.D., Derman R.J. What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis?. Osteoporos. Int. 2010, [Epub ahead of print].
186. Miller P.D., Chines A.A., Christiansen C., Hoeck H.C., Kendler D.L., Lewiecki E.M., Woodson G., Levine A.B., Constantine G., Delmas P.D. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J. Bone Miner. Res. 2008, 23:525-535.
187. Miossec P. Interleukin-17 in fashion, at last: ten years after its description, its cellular source has been identified. Arthritis Rheum. 2007, 56:2111-2115.
188. Miyaura C., Onoe Y., Inada M., Maki K., Ikuta K., Ito M., Suda T. Increased B-lymphopoiesis by interleukin 7 induces bone loss in mice with intact ovarian function: similarity to estrogen deficiency. Proc. Natl. Acad. Sci. USA 1997, 94:9360-9365.
189. Mor G., Sapi E., Abrahams V.M., Rutherford T., Song J., Hao X.Y., Muzaffar S., Kohen F. Interaction of the estrogen receptors with the Fas ligand promoter in human monocytes. J. Immunol. 2003, 170:114-122.
190. Morgan K., Clague R.B., Collins I., Ayad S., Phinn S.D., Holt P.J. Incidence of antibodies to native and denatured cartilage collagens (types II, IX, and XI) and to type I collagen in rheumatoid arthritis. Ann. Rheum. Dis. 1987, 46:902-907.
191. Morgan M.E., Sutmuller R.P., Witteveen H.J., van Duivenvoorde L.M., Zanelli E., Melief C.J., Snijders A., Offringa R., de Vries R.R., Toes R.E. CD25+ cell depletion hastens the onset of severe disease in collagen-induced arthritis. Arthritis Rheum. 2003, 48:1452-1460.
192. Mori H., Kitazawa R., Mizuki S., Nose M., Maeda S., Kitazawa S. RANK ligand, RANK, and OPG expression in type II collagen-induced arthritis mouse. Histochem. Cell. Biol. 2002, 117:283-292.
193. Morita Y., Yamamura M., Kawashima M., Harada S., Tsuji K., Shibuya K., Maruyama K., Makino H. Flow cytometric single-cell analysis of cytokine production by CD4+ T cells in synovial tissue and peripheral blood from patients with rheumatoid arthritis. Arthritis Rheum. 1998, 41:1669-1676.
194. Moskowitz M.A., Jick S.S., Burnside S., Wallis W.J., Dickson J.F., Hunter J.R., Jick H. The relationship of oral contraceptive use to rheumatoid arthritis. Epidemiology 1990, 1:153-156.
195. Mosmann T.R., Sad S. The expanding universe of T-cell subsets: Th1 Th2 and more. Immunol. Today 1996, 17:138-146.
196. Moxley G., Posthuma D., Carlson P., Estrada E., Han J., Benson L.L., Neale M.C. Sexual dimorphism in innate immunity. Arthritis Rheum. 2002, 46:250-258.
197. Mueck A.O., Seeger H. 2-methoxyestradiol-biology and mechanism of action. Steroids 2010, 75:625-631.
198. Nakae S., Nambu A., Sudo K., Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J. Immunol. 2003, 171:6173-6177.
199. Nakashima T., Kobayashi Y., Yamasaki S., Kawakami A., Eguchi K., Sasaki H., Sakai H. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem. Biophys. Res. Commun. 2000, 275:768-775.
200. Nestler J.E. Interleukin-1 stimulates the aromatase activity of human placental cytotrophoblasts. Endocrinology 1993, 132:566-570.
201. Newton C.J., Buric R., Trapp T., Brockmeier S., Pagotto U., Stalla G.K. The unliganded estrogen receptor (ER) transduces growth factor signals. J. Steroid Biochem. Mol. Biol. 1994, 48:481-486.
202. Nilsson N., Carlsten H. Estrogen induces suppression of natural killer cell cytotoxicity and augmentation of polyclonal B cell activation. Cell. Immunol. 1994, 158:131-139.
203. Notley C.A., Inglis J.J., Alzabin S., McCann F.E., McNamee K.E., Williams R.O. Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells. J. Exp. Med. 2008, 205:2491-2497.
204. Offner H., Adlard K., Zamora A., Vandenbark A.A. Estrogen potentiates treatment with T-cell receptor protein of female mice with experimental encephalomyelitis. J. Clin. Invest. 2000, 105:1465-1472.
205. Oida T., Xu L., Weiner H.L., Kitani A., Strober W. TGF-beta-mediated suppression by CD4+ CD25+ T cells is facilitated by CTLA-4 signaling. J. Immunol. 2006, 177:2331-2339.
206. Okamoto H., Yamamura M., Morita Y., Harada S., Makino H., Ota Z. The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis. Arthritis Rheum. 1997, 40:1096-1105.
207. Ostensen M. Sex hormones and pregnancy in rheumatoid arthritis and systemic lupus erythematosus. Ann. N Y Acad. Sci. 1999, 876:131-143. discussion 144.
208. Ostensen M., Aune B., Husby G. Effect of pregnancy and hormonal changes on the activity of rheumatoid arthritis. Scand. J. Rheumatol. 1983, 12:69-72.
209. Oursler M.J., Osdoby P., Pyfferoen J., Riggs B.L., Spelsberg T.C. Avian osteoclasts as estrogen target cells. Proc. Natl. Acad. Sci. USA 1991, 88:6613-6617.
210. Ozmen B., Kirmaz C., Aydin K., Kafesciler S.O., Guclu F., Hekimsoy Z. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis. Eur. Cytokine Netw. 2007, 18:148-153.
211. Pacifici R., Rifas L., McCracken R., Vered I., McMurtry C., Avioli L.V., Peck W.A. Ovarian steroid treatment blocks a postmenopausal increase in blood monocyte interleukin 1 release. Proc. Natl. Acad. Sci. USA 1989, 86:2398-2402.
212. Pacifici R., Brown C., Puscheck E., Friedrich E., Slatopolsky E., Maggio D., McCracken R., Avioli L.V. Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc. Natl. Acad. Sci. USA 1991, 88:5134-5138.
213. Pappas T.C., Gametchu B., Watson C.S. Membrane estrogen receptors identified by multiple antibody labeling and impeded-ligand binding. FASEB J. 1995, 9:404-410.
214. Pasare C., Medzhitov R. Toll pathway-dependent blockade of CD4+ CD25+ T cell-mediated suppression by dendritic cells. Science 2003, 299:1033-1036.
215. Pedram A., Razandi M., Levin E.R. Nature of functional estrogen receptors at the plasma membrane. Mol. Endocrinol. 2006, 20:1996-2009.
216. Pettersson K., Grandien K., Kuiper G.G., Gustafsson J.A. Mouse estrogen receptor beta forms estrogen response element-binding heterodimers with estrogen receptor alpha. Mol. Endocrinol. 1997, 11:1486-1496.
217. Pettit A.R., Ji H., von Stechow D., Muller R., Goldring S.R., Choi Y., Benoist C., Gravallese E.M. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am. J. Pathol. 2001, 159:1689-1699.
218. Pettit A.R., Walsh N.C., Manning C., Goldring S.R., Gravallese E.M. RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis. Rheumatology (Oxford) 2006, 45:1068-1076.
219. Pfeilschifter J., Koditz R., Pfohl M., Schatz H. Changes in proinflammatory cytokine activity after menopause. Endocr. Rev. 2002, 23:90-119.
220. Plotkin L.I., Aguirre J.I., Kousteni S., Manolagas S.C., Bellido T. Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. J. Biol. Chem. 2005, 280:7317-7325.
221. Plum S.M., Park E.J., Strawn S.J., Moore E.G., Sidor C.F., Fogler W.E. Disease modifying and antiangiogenic activity of 2-methoxyestradiol in a murine model of rheumatoid arthritis. BMC Musculoskelet. Disord. 2009, 10:46.
222. Poli V., Balena R., Fattori E., Markatos A., Yamamoto M., Tanaka H., Ciliberto G., Rodan G.A., Costantini F. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J. 1994, 13:1189-1196.
223. Poubelle P.E., Chakravarti A., Fernandes M.J., Doiron K., Marceau A.A. Differential expression of RANK, RANK-L, and osteoprotegerin by synovial fluid neutrophils from patients with rheumatoid arthritis and by healthy human blood neutrophils. Arthritis Res. Ther. 2007, 9:R25.
224. Prieto G.A., Rosenstein Y. Oestradiol potentiates the suppressive function of human CD4 CD25 regulatory T cells by promoting their proliferation. Immunology 2006, 118:58-65.
225. Rachon D., Mysliwska J., Suchecka-Rachon K., Wieckiewicz J., Mysliwski A. Effects of oestrogen deprivation on interleukin-6 production by peripheral blood mononuclear cells of postmenopausal women. J. Endocrinol. 2002, 172:387-395.
226. Ralston S.H., Russell R.G., Gowen M. Estrogen inhibits release of tumor necrosis factor from peripheral blood mononuclear cells in postmenopausal women. J. Bone Miner. Res. 1990, 5:983-988.
227. Ratkay L.G., Zhang D., Tonzetich J., Levy J.G., Waterfield J.D. Evaluation of a model for post-partum arthritis and the role of oestrogen in prevention of MRL-lpr associated rheumatic conditions. Clin. Exp. Immunol. 1994, 98:52-59.
228. Recker R.R., Davies K.M., Dowd R.M., Heaney R.P. The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women. A randomized, controlled trial. Ann. Intern. Med. 1999, 130:897-904.
229. Redlich K., Hayer S., Maier A., Dunstan C.R., Tohidast-Akrad M., Lang S., Turk B., Pietschmann P., Woloszczuk W., Haralambous S., Kollias G., Steiner G., Smolen J.S., Schett G. Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum. 2002, 46:785-792.
230. Rehman Q., Lane N.E. Bone loss. Therapeutic approaches for preventing bone loss in inflammatory arthritis. Arthritis Res. 2001, 3:221-227.
231. Revankar C.M., Cimino D.F., Sklar L.A., Arterburn J.B., Prossnitz E.R. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 2005, 307:1625-1630.
232. Revankar C.M., Mitchell H.D., Field A.S., Burai R., Corona C., Ramesh C., Sklar L.A., Arterburn J.B., Prossnitz E.R. Synthetic estrogen derivatives demonstrate the functionality of intracellular GPR30. ACS Chem. Biol. 2007, 2:536-544.
233. Rickard D.J., Hofbauer L.C., Bonde S.K., Gori F., Spelsberg T.C., Riggs B.L. Bone morphogenetic protein-6 production in human osteoblastic cell lines. Selective regulation by estrogen. J. Clin. Invest. 1998, 101:413-422.
234. Rifas L. T-cell cytokine induction of BMP-2 regulates human mesenchymal stromal cell differentiation and mineralization. J. Cell. Biochem. 2006, 98:706-714.
235. Riggs B.L., Khosla S., Melton L.J. Sex steroids and the construction and conservation of the adult skeleton. Endocr. Rev. 2002, 23:279-302.
236. Rijhsinghani A.G., Thompson K., Bhatia S.K., Waldschmidt T.J. Estrogen blocks early T cell development in the thymus. Am. J. Reprod. Immunol. 1996, 36:269-277.
237. Roark C.L., French J.D., Taylor M.A., Bendele A.M., Born W.K., O'Brien R.L. Exacerbation of collagen-induced arthritis by oligoclonal, IL-17-producing gamma delta T cells. J. Immunol. 2007, 179:5576-5583.
238. Roggia C., Gao Y., Cenci S., Weitzmann M.N., Toraldo G., Isaia G., Pacifici R. Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc. Natl. Acad. Sci. USA 2001, 98:13960-13965.
239. Romas E., Sims N.A., Hards D.K., Lindsay M., Quinn J.W., Ryan P.F., Dunstan C.R., Martin T.J., Gillespie M.T. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am. J. Pathol. 2002, 161:1419-1427.
240. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., Jackson R.D., Beresford S.A., Howard B.V., Johnson K.C., Kotchen J.M., Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 2002, 288:321-333.
241. Rudolphi U., Rzepka R., Batsford S., Kaufmann S.H., von der Mark K., Peter H.H., Melchers I. The B cell repertoire of patients with rheumatoid arthritis. II. Increased frequencies of IgG+ and IgA+ B cells specific for mycobacterial heat-shock protein 60 or human type II collagen in synovial fluid and tissue. Arthritis Rheum. 1997, 40:1409-1419.
242. Rutqvist L.E., Johansson H., Signomklao T., Johansson U., Fornander T., Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J. Natl. Cancer Inst. 1995, 87:645-651.
243. Saag K.G., Emkey R., Schnitzer T.J., Brown J.P., Hawkins F., Goemaere S., Thamsborg G., Liberman U.A., Delmas P.D., Malice M.P., Czachur M., Daifotis A.G. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N. Engl. J. Med. 1998, 339:292-299.
244. Saidenberg-Kermanac'h N., Corrado A., Lemeiter D., deVernejoul M.C., Boissier M.C., Cohen-Solal M.E. TNF-alpha antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis. Bone 2004, 35:1200-1207.
245. Sakaguchi S., Ono M., Setoguchi R., Yagi H., Hori S., Fehervari Z., Shimizu J., Takahashi T., Nomura T. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol. Rev. 2006, 212:8-27.
246. Sambrook P.N., Spector T.D., Seeman E., Bellamy N., Buchanan R.R., Duffy D.L., Martin N.G., Prince R., Owen E., Silman A.J., et al. Osteoporosis in rheumatoid arthritis. A monozygotic co-twin control study. Arthritis Rheum. 1995, 38:806-809.
247. Sato M., Kim J., Short L.L., Slemenda C.W., Bryant H.U. Longitudinal and cross-sectional analysis of raloxifene effects on tibiae from ovariectomized aged rats. J. Pharmacol. Exp. Ther. 1995, 272:1252-1259.
248. Sato M., Rippy M.K., Bryant H.U. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J. 1996, 10:905-912.
249. Sato K., Suematsu A., Okamoto K., Yamaguchi A., Morishita Y., Kadono Y., Tanaka S., Kodama T., Akira S., Iwakura Y., Cua D.J., Takayanagi H. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J. Exp. Med. 2006, 203:2673-2682.
250. Scheidt-Nave C., Bismar H., Leidig-Bruckner G., Woitge H., Seibel M.J., Ziegler R., Pfeilschifter J. Serum interleukin 6 is a major predictor of bone loss in women specific to the first decade past menopause. J. Clin. Endocrinol. Metab. 2001, 86:2032-2042.
251. Schett G., Redlich K., Hayer S., Zwerina J., Bolon B., Dunstan C., Gortz B., Schulz A., Bergmeister H., Kollias G., Steiner G., Smolen J.S. Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. Arthritis Rheum. 2003, 48:2042-2051.
252. Schmidt M., Hartung R., Capellino S., Cutolo M., Pfeifer-Leeg A., Straub R.H. Estrone/17beta-estradiol conversion to, and tumor necrosis factor inhibition by, estrogen metabolites in synovial cells of patients with rheumatoid arthritis and patients with osteoarthritis. Arthritis Rheum. 2009, 60:2913-2922.
253. Scott D.L. Prognostic factors in early rheumatoid arthritis. Rheumatology (Oxford) 2000, 39(Suppl. 1):24-29.
254. Seriolo B., Paolino S., Sulli A., Ferretti V., Cutolo M. Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis. Ann. N Y Acad. Sci. 2006, 1069:420-427.
255. Shigeyama Y., Pap T., Kunzler P., Simmen B.R., Gay R.E., Gay S. Expression of osteoclast differentiation factor in rheumatoid arthritis. Arthritis Rheum. 2000, 43:2523-2530.
256. Silverman S.L., Christiansen C., Genant H.K., Vukicevic S., Zanchetta J.R., de Villiers T.J., Constantine G.D., Chines A.A. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J. Bone Miner. Res. 2008, 23:1923-1934.
257. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., Nguyen H.Q., Wooden S., Bennett L., Boone T., Shimamoto G., DeRose M., Elliott R., Colombero A., Tan H.L., Trail G., Sullivan J., Davy E., Bucay N., Renshaw-Gegg L., Hughes T.M., Hill D., Pattison W., Campbell P., Sander S., Van G., Tarpley J., Derby P., Lee R., Boyle W.J. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319.
258. Sims N.A., Dupont S., Krust A., Clement-Lacroix P., Minet D., Resche-Rigon M., Gaillard-Kelly M., Baron R. Deletion of estrogen receptors reveals a regulatory role for estrogen receptors-beta in bone remodeling in females but not in males. Bone 2002, 30:18-25.
259. Sinigaglia L., Nervetti A., Mela Q., Bianchi G., Del Puente A., Di Munno O., Frediani B., Cantatore F., Pellerito R., Bartolone S., La Montagna G., Adami S. A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on bone mass in rheumatoid arthritis. J. Rheumatol. 2000, 27:2582-2589.
260. Smith C.L., Conneely O.M., O'Malley B.W. Modulation of the ligand-independent activation of the human estrogen receptor by hormone and antihormone. Proc. Natl. Acad. Sci. USA 1993, 90:6120-6124.
261. Spector T.D., Hall G.M., McCloskey E.V., Kanis J.A. Risk of vertebral fracture in women with rheumatoid arthritis. BMJ 1993, 306:558.
262. Srivastava S., Toraldo G., Weitzmann M.N., Cenci S., Ross F.P., Pacifici R. Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation. J. Biol. Chem. 2001, 276:8836-8840.
263. Staples J.E., Gasiewicz T.A., Fiore N.C., Lubahn D.B., Korach K.S., Silverstone A.E. Estrogen receptor alpha is necessary in thymic development and estradiol-induced thymic alterations. J. Immunol. 1999, 163:4168-4174.
264. Stefanick M.L. Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. Am. J. Med. 2005, 118(Suppl. 12B):64-73.
265. Stepan J.J., Alenfeld F., Boivin G., Feyen J.H., Lakatos P. Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis. Endocr. Regul. 2003, 37:225-238.
266. Stewart A., Mackenzie L.M., Black A.J., Reid D.M. Predicting erosive disease in rheumatoid arthritis. A longitudinal study of changes in bone density using digital X-ray radiogrammetry: a pilot study. Rheumatology (Oxford) 2004, 43:1561-1564.
267. Stolina M., Adamu S., Ominsky M., Dwyer D., Asuncion F., Geng Z., Middleton S., Brown H., Pretorius J., Schett G., Bolon B., Feige U., Zack D., Kostenuik P.J. RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis. J. Bone Miner. Res. 2005, 20:1756-1765.
268. Straub R.H. The complex role of estrogens in inflammation. Endocr. Rev. 2007, 28:521-574.
269. Straub R.H., Harle P., Atzeni F., Weidler C., Cutolo M., Sarzi-Puttini P. Sex hormone concentrations in patients with rheumatoid arthritis are not normalized during 12 weeks of anti-tumor necrosis factor therapy. J. Rheumatol. 2005, 32:1253-1258.
270. Stygar D., Westlund P., Eriksson H., Sahlin L. Identification of wild type and variants of oestrogen receptors in polymorphonuclear and mononuclear leucocytes. Clin. Endocrinol. (Oxf) 2006, 64:74-81.
271. Suzuki Y., Nishikaku F., Nakatuka M., Koga Y. Osteoclast-like cells in murine collagen induced arthritis. J. Rheumatol. 1998, 25:1154-1160.
272. Svensson L., Jirholt J., Holmdahl R., Jansson L. B cell-deficient mice do not develop type II collagen-induced arthritis (CIA). Clin. Exp. Immunol. 1998, 111:521-526.
273. Tada Y., Ho A., Koh D.R., Mak T.W. Collagen-induced arthritis in CD4- or CD8-deficient mice: CD8+ T cells play a role in initiation and regulate recovery phase of collagen-induced arthritis. J. Immunol. 1996, 156:4520-4526.
274. Tai P., Wang J., Jin H., Song X., Yan J., Kang Y., Zhao L., An X., Du X., Chen X., Wang S., Xia G., Wang B. Induction of regulatory T cells by physiological level estrogen. J. Cell. Physiol. 2008, 214:456-464.
275. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat. Rev. Immunol. 2007, 7:292-304.
276. Takemura S., Klimiuk P.A., Braun A., Goronzy J.J., Weyand C.M. T cell activation in rheumatoid synovium is B cell dependent. J. Immunol. 2001, 167:4710-4718.
277. Tamura T., Udagawa N., Takahashi N., Miyaura C., Tanaka S., Yamada Y., Koishihara Y., Ohsugi Y., Kumaki K., Taga T., et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc. Natl. Acad. Sci. USA 1993, 90:11924-11928.
278. Tarkowski A., Klareskog L., Carlsten H., Herberts P., Koopman W.J. Secretion of antibodies to types I and II collagen by synovial tissue cells in patients with rheumatoid arthritis. Arthritis Rheum. 1989, 32:1087-1092.
279. Taube M., Svensson L., Carlsten H. T lymphocytes are not the target for estradiol-mediated suppression of DTH in reconstituted female severe combined immunodeficient (SCID) mice. Clin. Exp. Immunol. 1998, 114:147-153.
280. Temin S. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. Gynecol. Oncol. 2009, 115:132-134.
281. Tengstrand B., Hafstrom I. Bone mineral density in men with rheumatoid arthritis is associated with erosive disease and sulfasalazine treatment but not with sex hormones. J. Rheumatol. 2002, 29:2299-2305.
282. Tengstrand B., Carlstrom K., Hafstrom I. Bioavailable testosterone in men with rheumatoid arthritis-high frequency of hypogonadism. Rheumatology (Oxford) 2002, 41:285-289.
283. Tengstrand B., Carlstrom K., Fellander-Tsai L., Hafstrom I. Abnormal levels of serum dehydroepiandrosterone, estrone, and estradiol in men with rheumatoid arthritis: high correlation between serum estradiol and current degree of inflammation. J. Rheumatol. 2003, 30:2338-2343.
284. Terato K., Shimozuru Y., Katayama K., Takemitsu Y., Yamashita I., Miyatsu M., Fujii K., Sagara M., Kobayashi S., Goto M., et al. Specificity of antibodies to type II collagen in rheumatoid arthritis. Arthritis Rheum. 1990, 33:1493-1500.
285. Terato K., Hasty K.A., Reife R.A., Cremer M.A., Kang A.H., Stuart J.M. Induction of arthritis with monoclonal antibodies to collagen. J. Immunol. 1992, 148:2103-2108.
286. Tomkinson A., Reeve J., Shaw R.W., Noble B.S. The death of osteocytes via apoptosis accompanies estrogen withdrawal in human bone. J. Clin. Endocrinol. Metab. 1997, 82:3128-3135.
287. Tomkinson A., Gevers E.F., Wit J.M., Reeve J., Noble B.S. The role of estrogen in the control of rat osteocyte apoptosis. J. Bone Miner. Res. 1998, 13:1243-1250.
288. Toraldo G., Roggia C., Qian W.P., Pacifici R., Weitzmann M.N. IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells. Proc. Natl. Acad. Sci. USA 2003, 100:125-130.
289. Trentham D.E., Townes A.S., Kang A.H. Autoimmunity to type II collagen an experimental model of arthritis. J. Exp. Med. 1977, 146:857-868.
290. Tsuboi M., Kawakami A., Nakashima T., Matsuoka N., Urayama S., Kawabe Y., Fujiyama K., Kiriyama T., Aoyagi T., Maeda K., Eguchi K. Tumor necrosis factor-alpha and interleukin-1beta increase the Fas-mediated apoptosis of human osteoblasts. J. Lab. Clin. Med. 1999, 134:222-231.
291. Turner R.T. Mice, estrogen, and postmenopausal osteoporosis. J. Bone Miner. Res. 1999, 14:187-191.
292. Ushiyama T., Ueyama H., Inoue K., Ohkubo I., Hukuda S. Expression of genes for estrogen receptors alpha and beta in human articular chondrocytes. Osteoarthritis Cartilage 1999, 7:560-566.
293. Valleala H., Laasonen L., Koivula M.K., Mandelin J., Friman C., Risteli J., Konttinen Y.T. Two year randomized controlled trial of etidronate in rheumatoid arthritis: changes in serum aminoterminal telopeptides correlate with radiographic progression of disease. J. Rheumatol. 2003, 30:468-473.
294. van Amelsfort J.M., Jacobs K.M., Bijlsma J.W., Lafeber F.P., Taams L.S. CD4(+)CD25(+) regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid. Arthritis Rheum. 2004, 50:2775-2785.
295. van Amelsfort J.M., van Roon J.A., Noordegraaf M., Jacobs K.M., Bijlsma J.W., Lafeber F.P., Taams L.S. Proinflammatory mediator-induced reversal of CD4+, CD25+ regulatory T cell-mediated suppression in rheumatoid arthritis. Arthritis Rheum. 2007, 56:732-742.
296. van den Brink H.R., van Everdingen A.A., van Wijk M.J., Jacobs J.W., Bijlsma J.W. Adjuvant oestrogen therapy does not improve disease activity in postmenopausal patients with rheumatoid arthritis. Ann. Rheum. Dis. 1993, 52:862-865.
297. van Essen H.W., Holzmann P.J., Blankenstein M.A., Lips P., Bravenboer N. Effect of raloxifene treatment on osteocyte apoptosis in postmenopausal women. Calcif. Tissue Int. 2007, 81:183-190.
298. van Roon J.A., Verhoef C.M., van Roy J.L., Gmelig-Meyling F.H., Huber-Bruning O., Lafeber F.P., Bijlsma J.W. Decrease in peripheral type 1 over type 2 T cell cytokine production in patients with rheumatoid arthritis correlates with an increase in severity of disease. Ann. Rheum. Dis. 1997, 56:656-660.
299. van Roon J.A., Verweij M.C., Wijk M.W., Jacobs K.M., Bijlsma J.W., Lafeber F.P. Increased intraarticular interleukin-7 in rheumatoid arthritis patients stimulates cell contact-dependent activation of CD4(+) T cells and macrophages. Arthritis Rheum. 2005, 52:1700-1710.
300. van Zeben D., Hazes J.M., Vandenbroucke J.P., Dijkmans B.A., Cats A. Diminished incidence of severe rheumatoid arthritis associated with oral contraceptive use. Arthritis Rheum. 1990, 33:1462-1465.
301. Vanderschueren D., Vandenput L., Boonen S., Lindberg M.K., Bouillon R., Ohlsson C. Androgens and bone. Endocr. Rev. 2004, 25:389-425.
302. Veldhoen M., Hocking R.J., Atkins C.J., Locksley R.M., Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006, 24:179-189.
303. Vidal O., Lindberg M.K., Hollberg K., Baylink D.J., Andersson G., Lubahn D.B., Mohan S., Gustafsson J.A., Ohlsson C. Estrogen receptor specificity in the regulation of skeletal growth and maturation in male mice. Proc. Natl. Acad. Sci. USA 2000, 97:5474-5479.
304. Vis M., Havaardsholm E.A., Haugeberg G., Uhlig T., Voskuyl A.E., van de Stadt R.J., Dijkmans B.A., Woolf A.D., Kvien T.K., Lems W.F. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2006, 65:1495-1499.
305. Volpe E., Servant N., Zollinger R., Bogiatzi S.I., Hupe P., Barillot E., Soumelis V. A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat. Immunol. 2008, 9:650-657.
306. Voskuhl R.R. Hormone-based therapies in MS. Int. MS J. 2003, 10:60-66.
307. Waites G.T., Whyte A. Effect of pregnancy on collagen-induced arthritis in mice. Clin. Exp. Immunol. 1987, 67:467-476.
308. Wakeling A.E., Dukes M., Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res. 1991, 51:3867-3873.
309. Wallach S., Cohen S., Reid D.M., Hughes R.A., Hosking D.J., Laan R.F., Doherty S.M., Maricic M., Rosen C., Brown J., Barton I., Chines A.A. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif. Tissue Int. 2000, 67:277-285.
310. Wang C., Dehghani B., Magrisso I.J., Rick E.A., Bonhomme E., Cody D.B., Elenich L.A., Subramanian S., Murphy S.J., Kelly M.J., Rosenbaum J.S., Vandenbark A.A., Offner H. GPR30 contributes to estrogen-induced thymic atrophy. Mol. Endocrinol. 2008, 22:636-648.
311. Weitzmann M.N., Roggia C., Toraldo G., Weitzmann L., Pacifici R. Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency. J. Clin. Invest. 2002, 110:1643-1650.
312. Windahl S.H., Vidal O., Andersson G., Gustafsson J.A., Ohlsson C. Increased cortical bone mineral content but unchanged trabecular bone mineral density in female ERbeta(-/-) mice. J. Clin. Invest. 1999, 104:895-901.
313. Windahl S.H., Hollberg K., Vidal O., Gustafsson J.A., Ohlsson C., Andersson G. Female estrogen receptor beta-/- mice are partially protected against age-related trabecular bone loss. J. Bone Miner. Res. 2001, 16:1388-1398.
314. Windahl S.H., Lagerquist M.K., Andersson N., Jochems C., Kallkopf A., Hakansson C., Inzunza J., Gustafsson J.A., van der Saag P.T., Carlsten H., Pettersson K., Ohlsson C. Identification of target cells for the genomic effects of estrogens in bone. Endocrinology 2007, 148:5688-5695.
315. Windahl S.H., Andersson N., Chagin A.S., Martensson U.E., Carlsten H., Olde B., Swanson C., Moverare-Skrtic S., Savendahl L., Lagerquist M.K., Leeb-Lundberg L.M., Ohlsson C. The role of the G protein-coupled receptor GPR30 in the effects of estrogen in ovariectomized mice. Am. J. Physiol. Endocrinol. Metab. 2009, 296:E490-E496.
316. Wing K., Larsson P., Sandstrom K., Lundin S.B., Suri-Payer E., Rudin A. CD4+ CD25+ FOXP3+ regulatory T cells from human thymus and cord blood suppress antigen-specific T cell responses. Immunology 2005, 115:516-525.
317. Wong B.R., Rho J., Arron J., Robinson E., Orlinick J., Chao M., Kalachikov S., Cayani E., Bartlett F.S., Frankel W.N., Lee S.Y., Choi Y. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J. Biol. Chem. 1997, 272:25190-25194.
318. Xu L., Kitani A., Fuss I., Strober W. Cutting edge: regulatory T cells induce CD4+CD25-Foxp3- T cells or are self-induced to become Th17 cells in the absence of exogenous TGF-beta. J. Immunol. 2007, 178:6725-6729.
319. Yamasaki D., Enokida M., Okano T., Hagino H., Teshima R. Effects of ovariectomy and estrogen replacement therapy on arthritis and bone mineral density in rats with collagen-induced arthritis. Bone 2001, 28:634-640.
320. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., Tomoyasu A., Yano K., Goto M., Murakami A., Tsuda E., Morinaga T., Higashio K., Udagawa N., Takahashi N., Suda T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 1998, 95:3597-3602.
321. Yilmaz L., Ozoran K., Gunduz O.H., Ucan H., Yucel M. Alendronate in rheumatoid arthritis patients treated with methotrexate and glucocorticoids. Rheumatol. Int. 2001, 20:65-69.
322. Yudoh K., Matsuno H., Nakazawa F., Yonezawa T., Kimura T. Reduced expression of the regulatory CD4+ T cell subset is related to Th1/Th2 balance and disease severity in rheumatoid arthritis. Arthritis Rheum. 2000, 43:617-627.
323. Yun T.J., Tallquist M.D., Aicher A., Rafferty K.L., Marshall A.J., Moon J.J., Ewings M.E., Mohaupt M., Herring S.W., Clark E.A. Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function. J. Immunol. 2001, 166:1482-1491.
324. Zaiss M.M., Axmann R., Zwerina J., Polzer K., Guckel E., Skapenko A., Schulze-Koops H., Horwood N., Cope A., Schett G. Treg cells suppress osteoclast formation: a new link between the immune system and bone. Arthritis Rheum. 2007, 56:4104-4112.
325. Zaman G., Jessop H.L., Muzylak M., De Souza R.L., Pitsillides A.A., Price J.S., Lanyon L.L. Osteocytes use estrogen receptor alpha to respond to strain but their ERalpha content is regulated by estrogen. J. Bone Miner. Res. 2006, 21:1297-1306.
326. Zhang Y.H., Heulsmann A., Tondravi M.M., Mukherjee A., Abu-Amer Y. Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J. Biol. Chem. 2001, 276:563-568.